Pasithea Therapeutics (KTTA) vs Psyence Biomedical (PBM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Pasithea Therapeutics (KTTA) has outperformed Psyence Biomedical (PBM) over the past year, gaining 63.9% versus a loss of 94.9%. Pasithea Therapeutics is the larger company by market cap ($17.6 million vs $15.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KTTA | PBM |
|---|---|---|
| Share price | $0.4787 | $2.97 |
| Market cap | $17.59M | $15.80M |
| 1-day change | -0.48% | +3.85% |
| YTD return | -62.89% | -89.90% |
| 1-year return | +63.94% | -94.90% |
| 5-year return | -99.40% | — |
| EPS (TTM) | $-1.38 | $-12.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-20.43M | $1.01M |
| 52-week high | $2.06 | $73.44 |
| 52-week low | $0.32 | $1.92 |
| Distance from 52-week high | -76.76% | -95.96% |
| Analyst consensus | none | — |
| Avg. price target upside | +526.70% | — |
| Average volume | 705.64K | 61.93K |
| Shares outstanding | 36.75M | 5.32M |
| Employees | 5 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KTTA has outperformed PBM by 158.8 percentage points over the past year.
About Pasithea Therapeutics
KTTA stock →Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Psyence Biomedical
PBM stock →Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
KTTA vs PBM FAQ
Which is bigger, Pasithea Therapeutics or Psyence Biomedical?
Pasithea Therapeutics (KTTA) is larger, with a market capitalization of $17.59M compared with $15.80M for Psyence Biomedical (PBM).
Which stock has performed better over the past year, KTTA or PBM?
KTTA returned +63.94% over the past 12 months, compared with -94.90% for PBM (price return, excluding dividends). Past performance does not predict future results.
Are Pasithea Therapeutics and Psyence Biomedical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.